Galderma Group AG
200.60
EUR
+12.85
(+6.84%)
ISIN
CH1335392721
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
USD
•
in mil. unless spec.Working Capital
USD
•
in mil. unless spec.Growth Rates
USD
•
in mil. unless spec.Semi-annual Revenue
USD
•
in mil. unless spec.Semi-annual Earnings Per Share
USD
•
in mil. unless spec.Semi-annual Dividends Per Share
USD
•
in mil. unless spec.Company Description
- CEO
- Flemming Ørnskov
- Full Time Employees
- 7,676
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Zählerweg 10 Zug ZG Switzerland 6300
- IPO Date
- Mar 22, 2024
- Website
- galderma.com
- Similar Companies
- Business
- Galderma Group AG (SIX: GALD) operates as a pure-play dermatology company dedicated to advancing treatments across injectable aesthetics, dermatological skincare and therapeutic dermatology; it offers a science-based portfolio of leading brands including Restylane and Restylane Skinboosters for hyaluronic acid fillers and skin rejuvenation, Dysport, Alluzience, Azzalure and Relfydess for botulinum toxin neuromodulators, Sculptra for collagen biostimulators, ALASTIN for professional peri-procedural and daily skincare regimens, Cetaphil for sensitive skin cleansing and moisturizing solutions, Benzac and Differin for acne treatments, Epiduo and Epiduo Forte gels for acne vulgaris, Soolantra and Oracea for rosacea, Nemluvio (nemolizumab) for prurigo nodularis and atopic dermatitis, Loceryl for onychomycosis, Actinica lotion for skin cancer risk reduction, Aklief for acne, Mirvaso for facial erythema, Metvix for actinic keratosis and Tri-Luma for melasma. Founded in 1981 as a joint venture between Nestlé and L'Oréal and headquartered in Zug, Switzerland, the company maintains operations in approximately 90 countries with key manufacturing and R&D sites in the United States, Sweden, France and Canada; it employs over 6,000 people and generates around 40% of net sales from the US market. In recent developments, Galderma listed on the SIX Swiss Exchange in March 2024 as the largest IPO in Switzerland since 2017, sold a 10% stake to L'Oréal in August 2024 establishing a strategic scientific partnership focused on skin biology and aesthetics while retaining independence, launched Nemluvio driving significant Therapeutic Dermatology growth with international expansion into China and India, committed over $650 million to US manufacturing investments in 2025 to meet rising demand, and executed a CHF 233 million share buyback in May 2025 as part of accelerated bookbuild offerings.
Company News
EQT exits Galderma Group AG in full via largest sponsor-backed block trade ever
EQT agrees to sale of shares in Galderma Group AG to L'Oréal S.A.
L’ORÉAL GROUPE TO REINFORCE ITS STRATEGIC INVESTMENT IN GALDERMA WITH AN ADDITIONAL 10% BRINGING ITS TOTAL PARTICIPATION TO 20%
LE GROUPE L’OREAL ANNONCE LE RENFORCEMENT DE SON INVESTISSEMENT STRATEGIQUE DANS GALDERMA EN PRENANT 10% SUPPLEMENTAIRES ET DETENIR AINSI 20% DU CAPITAL